| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients
|
Wills, Christopher
|
|
|
159 |
C |
p. 247-258
|
artikel
|
| 2 |
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact
|
Kondo, Naru
|
|
|
159 |
C |
p. 215-223
|
artikel
|
| 3 |
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects
|
Aldea, Mihaela
|
|
|
159 |
C |
p. 87-97
|
artikel
|
| 4 |
Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS)
|
Benhaim, Leonor
|
|
|
159 |
C |
p. 24-33
|
artikel
|
| 5 |
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region
|
De Giorgi, Ugo
|
|
|
159 |
C |
p. 237-246
|
artikel
|
| 6 |
Cutaneous melanoma attributable to UVR exposure in Denmark and Germany
|
Keim, Ulrike
|
|
|
159 |
C |
p. 98-104
|
artikel
|
| 7 |
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis
|
Tran, Son
|
|
|
159 |
C |
p. 259-274
|
artikel
|
| 8 |
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience
|
Lee, Yong-Pyo
|
|
|
159 |
C |
p. 167-173
|
artikel
|
| 9 |
First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
|
Majem, Margarita
|
|
|
159 |
C |
p. 174-181
|
artikel
|
| 10 |
Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis
|
Boutros, Andrea
|
|
|
159 |
C |
p. 154-166
|
artikel
|
| 11 |
HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2
|
Ho, Cassandra S.L.
|
|
|
159 |
C |
p. 16-23
|
artikel
|
| 12 |
High-resolution three-dimensional imaging for precise staging in melanoma
|
Merz, Simon F.
|
|
|
159 |
C |
p. 182-193
|
artikel
|
| 13 |
Impact of 18F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis
|
Woo, Sungmin
|
|
|
159 |
C |
p. 60-77
|
artikel
|
| 14 |
Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
|
Guiard, Emeline
|
|
|
159 |
C |
p. 125-132
|
artikel
|
| 15 |
Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA
|
Liang, Yu-Jing
|
|
|
159 |
C |
p. 133-143
|
artikel
|
| 16 |
Letter comments on: The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy
|
Hannoun-Levi, Jean-Michel
|
|
|
159 |
C |
p. 224-226
|
artikel
|
| 17 |
Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C
|
Marthick, James R.
|
|
|
159 |
C |
p. 52-55
|
artikel
|
| 18 |
Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid
|
Shi, Connie R.
|
|
|
159 |
C |
p. 34-37
|
artikel
|
| 19 |
Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations
|
Vassella, Erik
|
|
|
159 |
C |
p. 227-236
|
artikel
|
| 20 |
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort
|
Bossi, Paolo
|
|
|
159 |
C |
p. 194-204
|
artikel
|
| 21 |
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
|
Thielmann, Carl M.
|
|
|
159 |
C |
p. 113-124
|
artikel
|
| 22 |
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
|
Sakata, Yoshihiko
|
|
|
159 |
C |
p. 144-153
|
artikel
|
| 23 |
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment
|
Buttiron Webber, Tania
|
|
|
159 |
C |
p. 105-112
|
artikel
|
| 24 |
Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care
|
Garreffa, Emanuele
|
|
|
159 |
C |
p. 38-51
|
artikel
|
| 25 |
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation
|
Patsouris, Anne
|
|
|
159 |
C |
p. 283-295
|
artikel
|
| 26 |
SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients
|
Haeusler, Gabrielle M.
|
|
|
159 |
C |
p. 78-86
|
artikel
|
| 27 |
Significant decrease of the pathological stage I rectal carcinoma in the era of neoadjuvant therapy—A matter of concern
|
Stelzner, Sigmar
|
|
|
159 |
C |
p. 275-282
|
artikel
|
| 28 |
Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignancies
|
Koeppel, Florence
|
|
|
159 |
C |
p. 1-15
|
artikel
|
| 29 |
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients
|
Vicier, Cecile
|
|
|
159 |
C |
p. 205-214
|
artikel
|
| 30 |
The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy
|
Lythgoe, Mark P.
|
|
|
159 |
C |
p. 56-59
|
artikel
|
Tijdschrift beschrijving